tbuckley/cabot-search huggingface dataset:
Mr. Dooley and the practice of medicine: 1901
Authors: M. Kaufman
Journal: JAMA (1970)

The philosophical and entertaining Mr. Dooley, created by the Chicago humorist, Finley Peter Dunne, was one of the most interesting characters in the history of American comedy. Constantly commenting upon some timely topic, Dooley's Irish dialect revealed in wit and sarcasm the foibles of human nature. To some extent, Mr. Dooley was only mouthing the real sentiments of the public, a fact which made his remarks even more pertinent. In 1901,<i>Harper's Weekly Magazine</i>published Mr. Dooley's comments "On the Practice of Medicine" (<b>45</b>:698). In this short and amusing article, Finley Peter Dunne delightfully detailed the effects of the various developments in medical thought, and the popular reaction to the attempt of medicine to move from a rather haphazard art to a well-defined science. Dooley began by telling his friend Hennessey about the Christian Scientists who were beginning to practice medicine around the turn of the century. When a
Gastrointestinal Allergy
Authors: Franz J. Ingelfinger, Francis C. Lowell, William Franklin
Journal: New England Journal of Medicine (1949)

Laboratory TestsIn patients suspected of gastrointestinal allergy, demonstration of the allergic response has at times been sought by radiologic studies. For the most part, the patient has first been examined by means of a barium-in-water meal, followed in a few days by a similar examination, a suspected food being given with or a few hours after the barium suspension. In patients so examined, whether adults or children, the most common finding at the second test was delayed gastric emptying, usually interpreted as indicating allergic pyloric spasm or edema.31,40, 63 , 64 This interpretation, however, may be questioned on many counts. All foods, . . .
Cost of medical publications.
Journal: BMJ (1969)

PointersContraceptives and Cervical Carcinoma: Prevalence of carcinoma in situ was slightly but significantly less in women using diaphragms than in those on steroid contraceptives (p.195).Relapsing Thyrotoxicosis: In two groups of patients, one treated surgically and the other by drugs, recurrence was most satisfactorily treated by radioiodine despite the high incidence of hypothyroidism it induces (pp. 200and 203).Anaemia in Renal Failure: Study of iron kinetics confirms validity of haematocrit values as a guide to red cell mass in patients on main- tenance dialysis (p.206).Gastrectomy Sequelae: Neurological disease found in 14 patients many years after operation.Eleven had vitamin B12 deficiency, but only the three with signs of subacute combined without osteomalacia responded well to treatment (p.210).Bacteriuria in Pregnancy: Impairment of renal concentrating ability progresses with pregnancy, and the lower the maximum urinary osmolality the more difficult is treatment (p.212).Experimental Model for Leprosy: Inoculation of normal mice produces histological features of human leprosy after two or more years (p.216).Gingival Fibromatosis: Unusual manifestations of this hereditary disease (p.218).Knee Joint: Clinical examination (p.220).Today's Drugs: Newer diuretics-II (p.222).New approved names (p.224).Glandular Fever: Role of EB virus (p.190).
Multiple doses of anticholinergics are beneficial in severe, acute childhood asthma
Journal: BMJ (1998)

Multiple doses of anticholinergics are beneficial in severe, acute childhood asthmaThe addition of anticholinergics to 2 agonist inhalations remains controversial in the treatment of children and adolescents with asthma exacerbations.To examine the efficacy of three management strategies for adding anticholinergics to 2 agonists, Plotnick and Ducharme (p 971) systematically reviewed 10 randomised controlled trials, including single dose, multiple doses (predetermined protocol), and multiple doses (flexible protocol).Only the addition of multiple doses of anticholinergics to 2 agonists in a predetermined protocol reduced the risk of hospital admission (by 30%) and improved pulmonary function tests.Eleven children would need to be treated to avoid one admission.The use of anticholinergics in mild to moderate asthma is not supported by the available evidence.The number and size of pooled studies remain small, thus the conclusions are subject to change with future larger trials. Warm clothing and housing prevent excess winter mortalityCold weather increases death rates from heart disease, stroke, and all causes in western Europe.Donaldson et al studied mortality in Yakutsk in east Siberia, where temperatures average -26.6°C from October to March (p 978).Overall daily death rates did not rise even at temperatures of -48.2°C.An increase in deaths from respiratory disease below -20°C was balanced by a fall in deaths from injury at this temperature.The stable death rate is attributed to very warm outdoor clothing and housing as well as a reduction in outdoor trips at temperatures below -20°C.The authors suggest that most of the excess winter mortality in western Europe is preventable by personal cold protection.
THE ETIOLOGY OF CARCINOMA
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
La spirochetose meningée.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Futility in context
Authors: S. J. Youngner
Journal: JAMA (1990)

Two articles in this issue of<i>JAMA</i><sup>1,2</sup>make an important contribution to the growing debate about medical futility. The authors present a strong case that futile resuscitation need not be offered to patients and their families and may be denied when they request it. I have argued elsewhere that physicians might unreasonably diminish patient autonomy by acting on poorly defined notions of futility.<sup>3</sup>These articles make an equally important observation: by offering life-sustaining treatment that they consider futile, physicians may actually undermine patient and family autonomy. Such offers send a mixed message, implying a real choice when none exists. Furthermore, physicians have a socially sanctioned responsibility to evaluate, promote, and, when necessary, protect patients' best interests. As Tomlinson and Brody note, this role inevitably involves making value judgements as the physician weighs the potential harms and benefits of any given intervention. If such value judgments are "socially validated,"
CA 19–9 as a predictor of response and survival in patients with pancreatic cancer treated with gemcitabine and cisplatin based chemotherapy
Authors: B. Patel, L. Heilburn, A. Khanna, R. Venkatramanamoorthy, A. Shields, P. Philip, M. Zalupski, B. El-Rayes
Journal: Journal of Clinical Oncology (2005)

4189 Background: Radiologic evaluation of the efficacy of chemotherapy regimens in pancreatic cancer is difficult. The aim of this study was to evaluate the role of baseline CA 19–9 and the decrease in CA 19–9 after one cycle of chemotherapy as predictors of response, time to progression, and survival. Methods: Three consecutive phase II trials evaluating the role of gemcitabine and cisplatin based chemotherapy have been conducted by our group between 1997 and 2004. A total of 111 patients (pts) were enrolled on the trials. A retrospective chart review was performed for demographic data, best response status, time to progression, survival, and CA19–9 levels. Response by CA 19–9 (R-CA19–9) was defined as a decrease of ≥ 50% in CA 19–9 after the completion of the first cycle of chemotherapy. Results: The median age was 59 years with 60% males. Median performance status was 1. No significant difference was observed across the three trials with respect to age, sex, or performance status. Baseline CA19–9 was known for 102 pts, and was grouped into tertiles: < 300; 300–4,499; and ≥ 4,500 ng/mL. Lower baseline CA19–9 levels were not associated with higher response rate (p = 0.7568): 18%; 26%, and 21%, respectively. Lower baseline CA19–9 was weakly associated with longer overall survival (OS), but not significantly so (p = 0.1011). Median OS was 9.2, 6.9, and 5.9 months, respectively. Similar results were observed for time to progression (TTP), with p = 0.0977, and median TTP of 6.3, 5.3, and 4.2 months, respectively. The change in CA19–9 from baseline to the end of treatment cycle 1 was available for 68 pts. The pts with R-CA19–9 had a higher radiologic response rate (29%) than did the other pts (24%), but not significantly so (p = 0.7495). The pts with R-CA19–9 had longer OS (median 8.7 vs 7.1 months) and longer TTP (median 7.1 vs 5.4 months), but not significantly so (p > 0.42 for each endpoint). Conclusions: Both lower baseline CA19–9 and R-CA19–9 after treatment cycle 1 were each weakly but negatively associated with prognosis in our patient population. These data suggest that a 50% decrease in CA19–9 after the first cycle of chemotherapy is not a useful predictor of response, time to progression, or survival. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genentech Aventis, Lilly Oncology
Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers.
Authors: Apostolia Maria Tsimberidou, Borje Andersson, Chad Stewart, Hong Ma, Oliver Schoor, Dominik Maurer, Claudia Wagner, Arun Satelli, Jens Fritsche, Geoffery L Stephens, Ali Mohamed, Zoe Coughlin, Allie M Stungis, Kshipra M Gharpure, Patrick Hwu, Cassian Yee, Toni Weinschenk, Carsten Reinhardt, Steffen Walter, Harpreet Singh
Journal: Journal of Clinical Oncology (2018)

TPS3106 Background: Adoptive cellular therapy (ACT) has demonstrated substantial clinical progresses in hematologic cancers; however, only a small proportion of solid tumor patients have benefited from these advances due to i) lack of suitable immunotherapy targets with high specificity in solid tumors, ii) frequent relapse following immunotherapy to single targets often associated with loss of target expression in the tumor. The ACTolog® concept, utilizing antigen specific T cells (IMA101) against targets identified by the Immatics’ proprietary XPRESIDENT® technology, is intended to overcome these limitations by addressing multiple novel tumor antigens per patient. One key defining feature in this trial is the generation of robust T cells, where autologous T cells are primed against the expressed ACTolog targets in the presence of IL-21 followed by HLA tetramer-guided cell sorting and rapid expansion. This process has been shown to result in higher frequencies of central memory T cells, extended in vivo persistence, and a more robust clinical response. Methods: This study is a first-in-human phase I trial in patients with relapsed or refractory solid tumors expressing up to 4 targets from a warehouse of 8 cancer targets in which autologous T-cell products are manufactured against the most relevant tumor target peptides for individual patients. Key eligibility criteria include: HLA-A*02:01 phenotype, qPCR biomarker positive from a tumor biopsy, RECIST v1.1 measurable lesions, and ECOG status 0 or 1. At baseline, patients will undergo leukapheresis to collect mononuclear cells for manufacturing of IMA101 cells. Patients will receive anti-cancer therapy during the production phase. IMA101 will be infused after lymphodepletion regimen followed by low dose IL2. The primary objective is to assess safety and tolerability of IMA101. Secondary endpoints include overall response rate, PFS and OS. The translational objective includes the assessment of in vivo persistence and ex vivo characterization of transferred T cells in addition to evaluation of target expression in tumors. Enrollment in the study is currently ongoing. Clinical trial information: NCT02876510.
Have pacemakers found their way into too many patients?
Authors: W. A. Check
Journal: JAMA (1980)

A group of Brooklyn, NY, cardiologists has evidence that a nonbinding peer review system can reverse the dramatic expansion of an expensive technology—pacemaker implantation. The financial impact of such a retrenchment is potentially quite large, concluded Howard S. Friedman, MD, chief of cardiology at The Brooklyn Hospital, in his presentation at the recent meeting of the American Federation for Clinical Research in Washington, DC. "If this result can be extrapolated nationally, the health care cost due to pacemaker implantation can be reduced by several hundred million dollars per year," he said. Friedman explained that this estimate is based on a total first-year cost for pacemaker implantation of approximately $5,000. Several members of the audience praised the study but raised questions about patients who did not receive pacemakers subsequent to formation of the peer review committee. "What have you done to the survival of those who would have received the pacemaker
Nontraumatic Approaches to Assessing Cardiac Performance
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: N. J. ROBERT
Journal: JNCI Journal of the National Cancer Institute (1992)

BOOK REVIEWS Get access NICHOLAS J. ROBERT NICHOLAS J. ROBERT Fairfax Hematology-Oncology Associates3301 Woodbum Rd., Ste. 206 Annandale, VA 22003 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 84, Issue 10, 20 May 1992, Pages 806–807, https://doi.org/10.1093/jnci/84.10.806-a Published: 20 May 1992
Ptomaines, Leucomaines and Bacterial Proteids; or the Chemical Factors in the Causation of Disease.
Journal: JAMA (1892)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prostaglandins modulate the responsiveness of the gastric microcirculation of sodium nitroprusside in cirrhotic rats
Authors: J GERALDO
Journal: Hepatology (1996)

Cirrhotic rats have an increased susceptibility to ethanol-induced gastric injury, related to an inability to mount a defensive gastric hyperemic response to luminal irritants, and associated with an impaired reactivity of the gastric microcirculation to nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)-dependent vasodilators. Whether this hyporesponsiveness is in some way related to depressed prostaglandin synthesis by the stomach of cirrhotic rats is not clear. The aims of this study were to evaluate the role of NO and prostaglandins in the regulation of the gastric microcirculation under resting conditions and in response to administration of sodium nitroprusside, as well as to investigate the mechanisms of the hyporesponsiveness of the gastric microcirculation to nitrovasodilators. Cirrhosis was induced in rats by bile duct ligation, and controls had sham-operation. NG-nitro-L-arginine-methyl-ester (L- NAME) and indomethacin administration produced a greater reduction in gastric blood flow in cirrhotic rats than controls. Indomethacin pretreatment almost completely abolished the responsiveness to sodium nitroprusside (NaNP) in cirrhotic rats, while not affecting controls. Long-term administration of misoprostol to cirrhotic rats restored to normal the responsiveness to NaNP, whereas long-term administration of aspirin to healthy rats resulted in a hyporesponsiveness of the gastric microcirculation to NaNP similar to that seen in cirrhotic rats. We conclude that there are interactions between NO and prostaglandins in regulating gastric blood flow in both healthy and cirrhotic rats. The hyporesponsiveness of the gastric microcirculation of cirrhotic rats to a nitrovasodilator may occur as a consequence of prolonged depression of gastric prostaglandin synthesis.
Michigan a Summer- and Health-Resort State.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Breast cancer: how to mishandle misconduct
Authors: D. Rennie
Journal: JAMA (1994)

At the end of January 1994,<i>JAMA</i>accepted an article by Lee-Feldstein et al<sup>1</sup>on various prognostic factors related to survival of patients with breast cancer. These authors examined differences in operative approaches to breast cancer between types of hospitals and how mortality varied. Their data support the use of breast-conserving operations, a practice which they note is based largely on six randomized trials
Correction to: Identification of novel Y chromosome encoded transcripts by testis transcriptome analysis of mice with deletions of the Y chromosome long arm
Authors: Aminata Touré, Emily J. Clemente, Peter J. I. Ellis, Shantha K. Mahadevaiah, Obah A. Ojarikre, Penny A. F. Ball, Louise Reynard, Kate L. Loveland, Paul S. Burgoyne, Nabeel A. Affara
Journal: Genome biology (2019)

Following publication of the original article [1], the following error was reported: The actin control panel in Fig. 3 of this paper is reproduced from Fig. 7 of Touré et al, 2004 [2] by kind permission of the Genetics Society of America. Touré et al, 2004 used Northern blotting to show that the Y-linked genes Ssty1 and Ssty2 have reduced expression in a range of mouse genotypes with deletions on the Y chromosome long arm. This paper shows that two novel genes, Sly and Asty are also present on mouse Yq and have reduced expression in these deleted genotypes. A further companion paper was published in Human Molecular Genetics (Ellis et al, 2005 [3]) showing that X-linked genes are upregulated in the various deleted genotypes. Since two of the genotypes concerned are sterile and very hard to generate, all the Northern blot experiments in these papers were performed on a single membrane that was stripped and re-probed with a range of different X- and Y-linked genes. The same beta-actin loading control image thus necessarily applies to all the data presented, and was shown in all three papers. We regret that this was not mentioned appropriately in the Methods and figure legends at the time of publication.